Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?

Immunology Letters

Volumn 127, Issue 1, 2009, Pages 1-7

  Gagliani, Nicola ^a,b   Ferraro, Alessandra ^a,b   Roncarolo, Maria Grazia ^a,b   Battaglia, Manuela ^a,c  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Islet transplantation; Regulatory T cells; Type 1 diabetes

Indexed keywords

ALLOTRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL THERAPY; DIABETIC PATIENT; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; ISLETS OF LANGERHANS TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 70350716435     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2009.07.007     Document Type: Review

References (85)

1. Sakaguchi S., Yamaguchi T., Nomura T., and Ono M. Regulatory T cells and immune tolerance. Cell 133 (2008) 775-787
2. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., and Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212 (2006) 28-50
3. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 (2005) 345-352
4. + T reg cells. J Exp Med 203 (2006) 1701-1711
5. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203 (2006) 1693-1700
6. Miyara M., and Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13 (2007) 108-116
7. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997) 737-742
8. Haringer B., Lozza L., Steckel B., and Geginat J. Identification and characterization of IL-10/IFN-©-producing effector-like T cells with regulatory function in human blood. J Exp Med 206 (2009) 1009-1017
9. Atkinson M.A., and Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358 (2001) 221-229
10. Asano M., Toda M., Sakaguchi N., and Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184 (1996) 387-396
11. + regulatory T cells. Semin Immunol 16 (2004) 89-98
12. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K., et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 109 (2002) 131-140
13. + T-cells in type 1 diabetes. Diabetes 54 (2005) 1407-1414
14. high T-cell fraction. PLoS ONE 2 (2007) e146
15. + T-cells from patients with type 1 diabetes. Diabetes 54 (2005) 92-99
16. + regulatory T-cells. Diabetes 57 (2008) 2341-2347
17. high regulatory T cells in human autoimmune diabetes. J Autoimmun 24 (2005) 55-62
18. hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 154 (2008) 353-359
19. + regulatory T cells. J Immunol 181 (2008) 7350-7355
20. King C.G., Kobayashi T., Cejas P.J., Kim T., Yoon K., Kim G.K., et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 12 (2006) 1088-1092
21. Polanczyk M.J., Hopke C., Vandenbark A.A., and Offner H. Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol 19 (2007) 337-343
22. Tsutsumi Y., Jie X., Ihara K., Nomura A., Kanemitsu S., Takada H., et al. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes. Diabet Med 23 (2006) 1145-1150
23. Nielsen C., Hansen D., Husby S., Jacobsen B.B., and Lillevang S.T. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62 (2003) 492-497
24. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 113 (2004) 451-463
25. + cells at diagnosis predict glycemic control in type 1 diabetes. Clin Immunol 127 (2008) 138-143
26. Roncarolo M.G., and Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 7 (2007) 585-598
27. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199 (2004) 1455-1465
28. + regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 204 (2007) 191-201
29. Jaeckel E., von Boehmer H., and Manns M.P. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 54 (2005) 306-310
30. + T regulatory cells and T regulatory type 1 cells. Diabetes 55 (2006) 1571-1580
31. Caballero A., Fernandez N., Lavado R., Bravo M.J., Miranda J.M., and Alonso A. Tolerogenic response: allorecognition pathways. Transpl Immunol 17 (2006) 3-6
32. Miura Y., Thoburn C.J., Bright E.C., Phelps M.L., Shin T., Matsui E.C., et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104 (2004) 2187-2193
33. reg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108 (2006) 1291-1297
34. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 106 (2005) 2903-2911
35. high regulatory T cells. Blood 103 (2004) 2410-2416
36. high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol 33 (2005) 894-900
37. + regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 107 (2006) 1717-1723
38. Meloni F., Cascina A., Paschetto E., Marone Bianco A., Morosini M., Pellegrini C., et al. Monocyte chemoattractant protein-1 levels in bronchoalveolar lavage fluid of lung-transplanted patients treated with tacrolimus as rescue treatment for refractory acute rejection. Transplant Proc 35 (2003) 1523-1526
39. Demirkiran A., Kok A., Kwekkeboom J., Kusters J.G., Metselaar H.J., Tilanus H.W., et al. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl 12 (2006) 277-284
40. Pons J.A., Revilla-Nuin B., Baroja-Mazo A., Ramirez P., Martinez-Alarcon L., Sanchez-Bueno F., et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 86 (2008) 1370-1378
41. + T cells in human kidney transplant recipients. J Am Soc Nephrol 14 (2003) 1643-1651
42. + regulatory T cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 19 (2008) 2020-2026
43. Alvarez C.M., Opelz G., Garcia L.F., and Susal C. Expression of regulatory T-cell-related molecule genes and clinical outcome in kidney transplant recipients. Transplantation 87 (2009) 857-863
44. + T-cells. Nephrol Dial Transplant (2009)
45. Bacchetta R., Bigler M., Touraine J.L., Parkman R., Tovo P.A., Abrams J., et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 179 (1994) 493-502
46. Baker K.S., Roncarolo M.G., Peters C., Bigler M., DeFor T., and Blazar B.R. High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths. Bone Marrow Transplant 23 (1999) 1123-1129
47. Holler E., Roncarolo M.G., Hintermeier-Knabe R., Eissner G., Ertl B., Schulz U., et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 25 (2000) 237-241
48. Lin M.T., Storer B., Martin P.J., Tseng L.H., Gooley T., Chen P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349 (2003) 2201-2210
49. ® genotype of donor. Blood 106 (2005) 3995-4001
50. VanBuskirk A.M., Burlingham W.J., Jankowska-Gan E., Chin T., Kusaka S., Geissler F., et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 106 (2000) 145-155
51. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 193 (2001) 1311-1318
52. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196 (2002) 389-399
53. + regulatory T cells in nonlymphopenic hosts. J Leukoc Biol 82 (2007) 1053-1061
54. Nguyen V.H., Shashidhar S., Chang D.S., Ho L., Kambham N., Bachmann M., et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 111 (2008) 945-953
55. - regulatory cells mediate dominant transplantation tolerance. J Immunol 168 (2002) 5558-5565
56. Hara M., Kingsley C.I., Niimi M., Read S., Turvey S.E., Bushell A.R., et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 166 (2001) 3789-3796
57. + regulatory T lymphocytes. Nat Med 14 (2008) 88-92
58. + Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 118 (2008) 3619-3628
59. Dijke I.E., Caliskan K., Korevaar S.S., Maat A.P., Zondervan P.E., Balk A.H., et al. FOXP3 mRNA expression analysis in the peripheral blood and allograft of heart transplant patients. Transpl Immunol 18 (2008) 250-254
60. + T cell-mediated graft rejection: implications for anti-CD154 immunotherapy. J Immunol 169 (2002) 5401-5404
61. Battaglia M., Stabilini A., Draghici E., Gregori S., Mocchetti C., Bonifacio E., et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 55 (2006) 40-49
62. Huurman V.A., Velthuis J.H., Hilbrands R., Tree T.I., Gillard P., van der Meer-Prins P.M., et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant 9 (2009) 382-388
63. Campbell P.M., Senior P.A., Salam A., Labranche K., Bigam D.L., Kneteman N.M., et al. High risk of sensitization after failed islet transplantation. Am J Transplant 7 (2007) 2311-2317
64. Lobo P.I., Spencer C., Simmons W.D., Hagspiel K.D., Angle J.F., Deng S., et al. Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation. Transplant Proc 37 (2005) 3438-3440
65. Monti P., Scirpoli M., Maffi P., Ghidoli N., De Taddeo F., Bertuzzi F., et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 118 (2008) 1806-1814
66. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343 (2000) 230-238
67. Shapiro A.M., Ricordi C., Hering B.J., Auchincloss H., Lindblad R., Robertson R.P., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355 (2006) 1318-1330
68. Bellin M.D., Kandaswamy R., Parkey J., Zhang H.J., Liu B., Ihm S.H., et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 8 (2008) 2463-2470
69. Faradji R.N., Tharavanij T., Messinger S., Froud T., Pileggi A., Monroy K., et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation 86 (2008) 1658-1665
70. Froud T., Baidal D.A., Faradji R., Cure P., Mineo D., Selvaggi G., et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation 86 (2008) 1695-1701
71. Berney T., Ferrari-Lacraz S., Buhler L., Oberholzer J., Marangon N., Philippe J., et al. Long-term insulin-independence after allogeneic islet transplantation for type 1 diabetes: over the 10-year mark. Am J Transplant 9 (2009) 419-423
72. Waldmann H., Adams E., Fairchild P., and Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol Rev 212 (2006) 301-313
73. Battaglia M., Gregori S., Bacchetta R., and Roncarolo M.G. Tr1 cells: from discovery to their clinical application. Semin Immunol 18 (2006) 120-127
74. ® cell function in the NOD model of autoimmune diabetes. Stem Cells 21 (2003) 377-388
75. Worcester Human Islet Transplantation Group. Autoimmunity after islet-cell allotransplantation. N Engl J Med 355 (2006) 1397-1399
76. Sibley R.K., Sutherland D.E., Goetz F., and Michael A.F. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 53 (1985) 132-144
77. Tyden G., Reinholt F.P., Sundkvist G., and Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 335 (1996) 860-863
78. ® cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci USA 103 (2006) 17444-17449
79. Lakey J.R., Burridge P.W., and Shapiro A.M. Technical aspects of islet preparation and transplantation. Transpl Int 16 (2003) 613-632
80. Mercalli A., Sordi V., Ponzoni M., Maffi P., De Taddeo F., Gatti G., et al. Rapamycin induces a caspase-independent cell death in human monocytes. Am J Transplant 6 (2006) 1331-1341
81. Cernea S., and Pozzilli P. New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes. Diabet Med 25 (2008) 1259-1267
82. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., and Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5 (1999) 1298-1302
83. Rutella S., Zavala F., Danese S., Kared H., and Leone G. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 175 (2005) 7085-7091
84. Baidal D.A., Faradji R.N., Messinger S., Froud T., Monroy K., et al. Early metabolic markers of islet allograft dysfunction. Transplantation 87 (2009) 689-697
85. Serafini G, Andreani M, Testi M, Battarra M, Bontadini A, Fleischhauer K, et al. Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica. 2009 Jul 16.[Epub ahead of print].